Literature DB >> 18019677

Profiling of fluorouracil-related genes by microdissection technique in hepatocellular carcinoma.

Tsubasa Takahashi1, Hiroshi Yoshida, Yasuhiro Mamada, Nobuhiko Taniai, Yoshiaki Mizuguchi, Tetsuya Shimizu, Daisuke Kakinuma, Yoshinori Ishikawa, Koho Akimaru, Yuichi Sugisaki, Takashi Tajiri.   

Abstract

BACKGROUND/AIMS: 5-fluorouracil (5-FU)-related metabolic enzymes, including dihydropyrimidine dehydrogenase (DPD), thymidylate synthase (TS), thymidylate phosphorylase (TP), and orotate phosphoribosyl transferase (OPRT) are initial, rate-limiting enzymes in the metabolism of 5-FU. The therapeutic implications of these enzymes in hepatocellular carcinoma (HCC) remain poorly understood. We used a newly developed laser-captured microdissection technique combined with RNA extraction to examine the mRNA levels of 5-FU-related metabolic enzymes in HCC and adjacent liver tissue.
METHODOLOGY: The study material comprised 43 paired specimens of HCC and adjacent liver tissue. The mRNA levels of 5-FU-related metabolic enzymes were quantified by real-time reverse-transcriptase polymerase chain reaction combined with laser-captured microdissection.
RESULTS: The DPD mRNA level in HCC (4.31 +/- 4.21) was lower than that in adjacent liver (6.53 +/- 2.93) (p < 0.001). The TS mRNA level in HCC (3.55 +/- 2.54) was higher than that in adjacent liver (1.90 +/- 0.11) p < 0.001). The TP and the OPRT mRNA levels did not differ significantly between HCC and adjacent liver. The TS mRNA level of HCC with portal invasion (4.47 +/- 2.76) was higher than that of HCC without portal invasion (2.71 +/- 1.96) (p = 0.015). The DPD mRNA level of HCC with septum formation (4.89 +/- 4.82) was significantly higher than that of HCC without septum formation (2.12 +/- 0.61) (p < 0.027). The OPRT mRNA level of poorly differentiated HCC (1.18 +/- 0.49) was lower than that of moderately or well-differentiated HCC (2.42 +/- 1.82) (p = 0.037).
CONCLUSIONS: The DPD mRNA level was lower and the TS mRNA level was higher in HCC than in adjacent liver. Our results will hopefully stimulate further investigations designed to optimize the use of 5-FU in patients with HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18019677

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

1.  Elevated levels of mRNAs encoding dihydropyrimidine dehydrogenase and thymidylate synthase are associated with improved survival of patients with hepatocellular carcinoma treated with S-1.

Authors:  Yusuke Okano; Hidekazu Kuramochi; Go Nakajima; Satoshi Katagiri; Masakazu Yamamoto
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

2.  Complete remission of multiple recurrent hepatocellular carcinomas by oral administration of enteric-coated tegafur/uracil in a patient with huge hepatocellular carcinoma extending to the inferior vena cava after hepatic resection: analysis of mRNA expression of fluoropyrimidine metabolism enzymes in the primary tumor.

Authors:  Masanori Matsuda; Shugo Shiba; Masami Asakawa; Hiroshi Kono; Hideki Fujii
Journal:  Int J Clin Oncol       Date:  2009-07-11       Impact factor: 3.402

3.  Identification of genes conferring resistance to 5-fluorouracil.

Authors:  Byoung Kwon Yoo; Rachel Gredler; Nicollaq Vozhilla; Zao-zhong Su; Dong Chen; Talitha Forcier; Khalid Shah; Utsav Saxena; Ulla Hansen; Paul B Fisher; Devanand Sarkar
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-21       Impact factor: 11.205

4.  Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment.

Authors:  Hongyun Zhao; Yuanyuan Zhao; Ying Guo; Yan Huang; Suxia Lin; Cong Xue; Fei Xu; Yang Zhang; Liping Zhao; Zhihuang Hu; Li Zhang
Journal:  Onco Targets Ther       Date:  2013-07-03       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.